Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird

Enliven Therapeutics (NASDAQ:ELVN) had its target price lifted by Robert W. Baird from $40.00 to $52.00 in a research note published on Monday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities analysts also recently commented on ELVN. The Goldman Sachs Group assumed coverage on Enliven Therapeutics in a research report on Monday. They set a “buy” rating and a $37.00 price objective for the company. HC Wainwright boosted their price objective on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th. Finally, Jones Trading lowered their price target on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a report on Friday, May 16th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $39.60.

Enliven Therapeutics Trading Up 5.4%

Shares of NASDAQ:ELVN opened at $23.09 on Monday. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -12.15 and a beta of 0.79. The business has a 50-day moving average price of $18.30 and a 200 day moving average price of $20.60. Enliven Therapeutics has a 12-month low of $13.30 and a 12-month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, equities research analysts predict that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.34, for a total value of $135,606.78. Following the transaction, the chief operating officer now directly owns 303,309 shares in the company, valued at $6,169,305.06. This trade represents a 2.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the completion of the transaction, the insider now owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. This trade represents a 1.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 88,611 shares of company stock valued at $1,676,289 over the last quarter. Insiders own 25.90% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of large investors have recently modified their holdings of ELVN. Polar Capital Holdings Plc grew its stake in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. Boxer Capital Management LLC acquired a new position in shares of Enliven Therapeutics in the 4th quarter worth approximately $15,106,000. Janus Henderson Group PLC grew its position in shares of Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock worth $30,001,000 after acquiring an additional 290,153 shares in the last quarter. FMR LLC grew its position in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company’s stock worth $146,157,000 after acquiring an additional 199,692 shares in the last quarter. Finally, Pictet Asset Management Holding SA grew its position in shares of Enliven Therapeutics by 16.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock worth $21,877,000 after acquiring an additional 135,969 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.